Tech Company Inital Public Offerings
Blueprint Medicines IPO
On 4/30/2015, Blueprint Medicines went public.
Transaction Overview
Company Name
Announced On
4/30/2015
Transaction Type
IPO
Amount
$145,800,000
Proceeds Purpose
Proceeds purposes are on file with company statements at the SEC.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
45 Sidney St. 200
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffery Albers
Chief Medical Officer
Anthony Boral
Chief Scientific Officer
Marion Dorsch
Executive Vice President
Christoph Lengauer
VP - Bus. Development
Kate Haviland
VP - Finance
Michael Landsittel
VP - General Counsel
Tracey McCain
VP - Human Resources
Debbie Durso-Bumpus
VP - Operations
Christopher Murray
Browse more venture capital transactions:
Prev: 4/30/2015: CRISPR Therapeutics venture capital transaction
Next: 4/30/2015: ThreatQuotient venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs